Want to see ADOCY full AI Analyst Report?

Adocia (ADOCY) Price & Analysis

15 Followers

ADOCY Stock Chart & Stats

$4.37

$0.00(0.00%)

At close: Sep 01 4:00 PM EDT

$4.37

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$4.26 - $12.55

Previous CloseN/A

Volume11.00

Average Volume (3M)0.00

Market Cap

$90.81M

Enterprise Value$137.13

Total Cash (Recent Filing)$17.25M

Total Debt (Recent Filing)$8.90M

Price to Earnings (P/E)―

Beta1.29

Next Earnings

Sep 24, 2026

EPS Estimate

-0.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.87

Shares Outstanding20,053,057

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.55

Price to Book (P/B)132.14

Price to Sales (P/S)139.00

P/FCF Ratio-30.16

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.59

Revenue Forecast (FY)$16.43M

Bulls Say, Bears Say

Bulls Say

Partnership-driven ModelA partnership/licensing model shifts commercialization and capex burden to larger pharma partners, enabling Adocia to monetize R&D through upfronts, milestones and royalties. This durable model can scale value capture without large internal commercial investment.

Proprietary Formulation TechOwning formulation and delivery platforms for insulin/metabolic injectables is a structural competitive advantage. It can create high partnering value, support differentiated products and generate recurring licensing opportunities across multiple molecules and partners over time.

Improving Cash Burn & EquityNarrowing operating cash losses and returning to positive equity in 2025 indicate improving financial dynamics and better runway. If sustained, this reduces near-term financing dependence and strengthens negotiating leverage with partners and investors.

Bears Say

Persistent Net LossesConsistent annual losses and an extreme 2025 net margin reflect a structural inability so far to cover operating costs with revenue. This weak profitability undermines internal reinvestment capacity and necessitates ongoing external funding absent material commercial success.

Highly Volatile RevenueLarge year-to-year swings in revenue suggest reliance on lumpy milestone or partnership receipts. This structural volatility complicates planning, forecasting and cash management, increasing the risk that adverse timing disrupts operations or triggers dilutive financing.

High LeverageA debt-to-equity ratio near 6 and prior negative equity show meaningful leverage relative to company size. High leverage reduces financial flexibility, raises refinancing risk, and can force dilutive equity raises if clinical or partnership timelines slip.

ADOCY FAQ

What was Adocia SA’s price range in the past 12 months?

Adocia SA lowest stock price was $4.26 and its highest was $12.55 in the past 12 months.

What is Adocia SA’s market cap?

Adocia SA’s market cap is $90.81M.

When is Adocia SA’s upcoming earnings report date?

Adocia SA’s upcoming earnings report date is Sep 24, 2026 which is in 56 days.

How were Adocia SA’s earnings last quarter?

Adocia SA released its earnings results on Apr 21, 2026. The company reported -$0.453 earnings per share for the quarter, beating the consensus estimate of -$0.673 by $0.22.

Is Adocia SA overvalued?

According to Wall Street analysts Adocia SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Adocia SA pay dividends?

Adocia SA does not currently pay dividends.

What is Adocia SA’s EPS estimate?

Adocia SA’s EPS estimate is -0.5.

How many shares outstanding does Adocia SA have?

Adocia SA has 20,053,057 shares outstanding.

What happened to Adocia SA’s price movement after its last earnings report?

Adocia SA reported an EPS of -$0.453 in its last earnings report, beating expectations of -$0.673. Following the earnings report the stock price went up 16.641%.

Which hedge fund is a major shareholder of Adocia SA?

Currently, no hedge funds are holding shares in ADOCY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Adocia SA

Adocia S.A. is a clinical-stage biotechnology company dedicated to the research and development of novel formulations of established therapeutic proteins and peptides. Its primary focus is on addressing diabetes and various other metabolic disorders. Central to its work is the exclusive BioChaperone technological platform, engineered to significantly enhance the performance characteristics of therapeutic proteins. Its robust clinical pipeline features several advanced candidates: Insulin-based treatments: Including BioChaperone Lispro U100 and U200, which are ultra-fast-acting versions derived from rapid insulin lispro; BioChaperone Combo, combining long-acting insulin glargine with rapid-acting insulin lispro; and BioChaperone LisPram, which pairs prandial insulin with pramlintide. Hypoglycemia treatment: BioChaperone Glucagon, an aqueous human glucagon solution specifically designed to manage severe low blood sugar episodes. Other: M1Pram, a derivative combining insulin glargine and pramlintide. The preclinical development programs further expand into bi-hormonal products such as BioChaperone AsPram, a combination of rapid insulin aspart and pramlintide, and BioChaperone Glargine Liraglutidea, a co-formulation of insulin glargine and a GLP-1 receptor analogue. Additionally, its preclinical portfolio targets obesity with multi-hormonal products like BioChaperone GluExe (glucagon and exenatide), PramExe (pramlintide and exenatide), and BioChaperone PramGluExe, a tripartite blend of pramlintide, glucagon, and exenatide. Adocia has forged a strategic partnership with Tonghua Dongbao Pharmaceutical Co., Ltd. for the development and market introduction of BioChaperone Lispro and BioChaperone Combo across China, other parts of Asia, and the Middle East. Established in 2005, the company maintains its headquarters in Lyon, France.